
Teva and Sanofi Unveil Encouraging Phase 2b Results of Duvakitug (anti-TL1A) in Ulcerative Colitis and Crohn’s Disease at ECCO 2025: Reinforcing Best-in-Class Potential
New Findings from the RELIEVE UCCD Study: Duvakitug’s Efficacy and Safety Across Doses and Subgroups Teva Pharmaceuticals, a leading global pharmaceutical company, recently announced new findings from the RELIEVE UCCD study, which further supports the overall efficacy and safety of Duvakitug in all pre-specified subgroups across various doses. This study, which was conducted in collaboration…